Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherAssets,changeToLiabilities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,netBorrowings,changeToInventory,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,EVOK,7811384.0,32372000,277825,,-2605495,,-2605495,2338295,25670,-2590450,-2590450,,-123339,,,,0,90421,2680871,64751,-15045,,-2605495,-2605495,109298703.0,11484566.0,7811384.0,5009038.0,19295950.0,3237.0,11703.0,-101490556.0,235583.0,18185974.0,6248983.0,119926.0,19176024.0,127795.0,5000000.0,236044.0,691225.0,,-604126.0,13070154.0,-96194.0,14375000.0,10117035.0,-2953119.0,-104484.0,-1304846.0,457180.0,,,12927041.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Evoke Pharma, Inc.",False,False,NCM,1.15,1630511040,-0.01999998,1.17,1.18,1.1407,42248,REGULAR,0,4,-1.7094002,1.1407 - 1.18,1.17,1.15,1.16,12,9,finmb_35230943,"Evoke Pharma, Inc.",NasdaqCM,USD,567692,216066,0.19,0.19791667,0.96 - 5.58,-4.43,-0.7939068,0.96,5.58,1620835507,1628107200,1628539200,-0.514,-0.31,-0.29,-3.9655173,0.241,1.1486111,0.0013889074,0.0012092061,1.6749276,-0.5249276,-0.31340316,37227800,-3.7096772,4.7717843,15,America/New_York,EDT,-14400000,1.06,,,5.58,0.96,1.1486,1.6749,567.69k,216.07k,32.37M,,29.68M,3.05%,14.05%,988.06k,2.63,3.15%,3.05%,1.25M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-12,203.80%",-72.30%,-260.32%,113.44k,0.00,,-63.69k,,-13.97M,-0.5140,,18.19M,0.56,5.12M,65.54,3.07,0.24,-8.03M,-2.99M,Value,92075,Healthcare,5,"Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.",Solana Beach,858 345 1494,CA,1609372800,United States,http://www.evokepharma.com,86400,420 Stevens Avenue,Drug Manufacturers—Specialty & Generic,Suite 370
t-1,EVOK,-3214623.0,32372000,103846,,-2267862,,-2267862,2041548,-63692,-2209086,-2209086,,-59552,,,,0,23020,2232106,86712,-58776,,-2267862,-2267862,95667776.0,12648671.0,-3214623.0,5000000.0,9434048.0,2662.0,30300.0,-98885061.0,112994.0,8068939.0,7535677.0,141705.0,9280792.0,23311.0,5000000.0,236480.0,1273572.0,11551.0,914805.0,3499787.0,4454608.0,499787.0,1788283.0,-1711504.0,-104484.0,-1304846.0,-4576575.0,3000000.0,-236480.0,1745115.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Evoke Pharma, Inc.",False,False,NCM,1.15,1630511040,-0.01999998,1.17,1.18,1.1407,42248,REGULAR,0,4,-1.7094002,1.1407 - 1.18,1.17,1.15,1.16,12,9,finmb_35230943,"Evoke Pharma, Inc.",NasdaqCM,USD,567692,216066,0.19,0.19791667,0.96 - 5.58,-4.43,-0.7939068,0.96,5.58,1620835507,1628107200,1628539200,-0.514,-0.31,-0.29,-3.9655173,0.241,1.1486111,0.0013889074,0.0012092061,1.6749276,-0.5249276,-0.31340316,37227800,-3.7096772,4.7717843,15,America/New_York,EDT,-14400000,1.06,,,5.58,0.96,1.1486,1.6749,567.69k,216.07k,32.37M,,29.68M,3.05%,14.05%,988.06k,2.63,3.15%,3.05%,1.25M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-12,203.80%",-72.30%,-260.32%,113.44k,0.00,,-63.69k,,-13.97M,-0.5140,,18.19M,0.56,5.12M,65.54,3.07,0.24,-8.03M,-2.99M,Value,92075,Healthcare,5,"Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.",Solana Beach,858 345 1494,CA,1609372800,United States,http://www.evokepharma.com,86400,420 Stevens Avenue,Drug Manufacturers—Specialty & Generic,Suite 370
t-2,EVOK,-1923415.0,32372000,205032,,-2129105,,-2129105,1874578,0,-2079610,-2079610,,-50528,,,,0,0,2079610,0,-49495,,-2129105,-2129105,94691151.0,8674314.0,-1923415.0,5000000.0,6750899.0,2633.0,11551.0,-96617199.0,53005.0,6280656.0,6621309.0,36115.0,6714784.0,,2000000.0,86145.0,765603.0,,-19860.0,100792.0,-193579.0,100792.0,-1709736.0,-1810528.0,-104484.0,-1304846.0,532016.0,3000000.0,-236480.0,93475.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Evoke Pharma, Inc.",False,False,NCM,1.15,1630511040,-0.01999998,1.17,1.18,1.1407,42248,REGULAR,0,4,-1.7094002,1.1407 - 1.18,1.17,1.15,1.16,12,9,finmb_35230943,"Evoke Pharma, Inc.",NasdaqCM,USD,567692,216066,0.19,0.19791667,0.96 - 5.58,-4.43,-0.7939068,0.96,5.58,1620835507,1628107200,1628539200,-0.514,-0.31,-0.29,-3.9655173,0.241,1.1486111,0.0013889074,0.0012092061,1.6749276,-0.5249276,-0.31340316,37227800,-3.7096772,4.7717843,15,America/New_York,EDT,-14400000,1.06,,,5.58,0.96,1.1486,1.6749,567.69k,216.07k,32.37M,,29.68M,3.05%,14.05%,988.06k,2.63,3.15%,3.05%,1.25M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-12,203.80%",-72.30%,-260.32%,113.44k,0.00,,-63.69k,,-13.97M,-0.5140,,18.19M,0.56,5.12M,65.54,3.07,0.24,-8.03M,-2.99M,Value,92075,Healthcare,5,"Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.",Solana Beach,858 345 1494,CA,1609372800,United States,http://www.evokepharma.com,86400,420 Stevens Avenue,Drug Manufacturers—Specialty & Generic,Suite 370
t-3,EVOK,-373676.0,32372000,5782094,,-6967395,,-6967395,1182872,0,-6964966,-6964966,,-2914,,,,0,0,6964966,0,-2429,,-6967395,-6967395,94111817.0,8640732.0,-373676.0,5000000.0,8267056.0,2601.0,11551.0,-94488094.0,,7990392.0,6640732.0,71211.0,8195845.0,,2000000.0,,604832.0,,-179682.0,5413284.0,228042.0,3309116.0,3857204.0,-1556080.0,-104484.0,-1304846.0,5362955.0,2104168.0,-236480.0,1555113.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Evoke Pharma, Inc.",False,False,NCM,1.15,1630511040,-0.01999998,1.17,1.18,1.1407,42248,REGULAR,0,4,-1.7094002,1.1407 - 1.18,1.17,1.15,1.16,12,9,finmb_35230943,"Evoke Pharma, Inc.",NasdaqCM,USD,567692,216066,0.19,0.19791667,0.96 - 5.58,-4.43,-0.7939068,0.96,5.58,1620835507,1628107200,1628539200,-0.514,-0.31,-0.29,-3.9655173,0.241,1.1486111,0.0013889074,0.0012092061,1.6749276,-0.5249276,-0.31340316,37227800,-3.7096772,4.7717843,15,America/New_York,EDT,-14400000,1.06,,,5.58,0.96,1.1486,1.6749,567.69k,216.07k,32.37M,,29.68M,3.05%,14.05%,988.06k,2.63,3.15%,3.05%,1.25M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-12,203.80%",-72.30%,-260.32%,113.44k,0.00,,-63.69k,,-13.97M,-0.5140,,18.19M,0.56,5.12M,65.54,3.07,0.24,-8.03M,-2.99M,Value,92075,Healthcare,5,"Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase III clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.",Solana Beach,858 345 1494,CA,1609372800,United States,http://www.evokepharma.com,86400,420 Stevens Avenue,Drug Manufacturers—Specialty & Generic,Suite 370
